CALIDI B Stock

CLDI

US3207034089

Biotechnology & Medical Research

Market Closed - NYSE Other stock markets 16:00:00 2026-07-31 EDT			5-day change	1st Jan Change
1.640 ^USD	+9.86%		+2.50%	-91.24%

07-27	Calidi Biotherapeutics, Inc. Presents New Data On Cytotoxicity And IL-15 SA Expression In Human And Murine Tumor Cells	CI
07-20	Calidi Biotherapeutics to Effect 1-for-16 Reverse Stock Split	MT

Analysts' recommendations: CALIDI B

25-08-20	Top Midday Decliners	MT
24-06-27	Ladenburg Thalmann Initiates Calidi Biotherapeutics at Buy	MT
24-03-21	H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating	MT
23-11-22	HC Wainwright Starts Calidi Biotherapeutics With Buy Rating, $11 Price Target	MT
23-10-09	Baird Starts Calidi Biotherapeutics With Outperform Rating, Price Target is $9	MT

More recommendations

Managers and Directors: CALIDI B

Manager	Title	Age	Since
Eric Poma CEO	Chief Executive Officer	54	2025-04-21
Andrew Jackson DFI	Director of Finance/CFO	57	2023-10-29
Guy Clifton CTO	Chief Tech/Sci/R&D Officer	-	2025-04-09

Director	Title	Age	Since
Scott Leftwich BRD	Director/Board Member	65	2019-04-30
James Schoeneck CHM	Chairman	68	2025-03-31
Alan Stewart BRD	Director/Board Member	62	2023-10-09

More insiders

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patientâ€™s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-31	US$1.640	+9.86%	464,476
26-07-29	US$1.493	-13.13%	146,606
26-07-28	US$1.718	-1.92%	159,041
26-07-27	US$1.752	+9.50%	462,648
26-07-24	US$1.600	-4.76%	2,508,593

Delayed Quote NYSE

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Stock Market
Stocks
CLDI Stock

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	1.99M 1.73M 1.61M 1.48M 2.8M 190M 2.84M 19.03M 7.47M 94.8M 7.49M 7.33M 318M	P/E 2024	-0.39x	P/E 2025	-0.2x
Enterprise Value	-1.04M -905K -842K -773K -1.46M -99.39M -1.48M -9.93M -3.9M -49.48M -3.91M -3.82M -166M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	98.13%	Yield 2024 *	-	Yield 2025	-

07-27	Calidi Biotherapeutics, Inc. Presents New Data On Cytotoxicity And IL-15 SA Expression In Human And Murine Tumor Cells	CI
07-20	Calidi Biotherapeutics to Effect 1-for-16 Reverse Stock Split	MT
07-16	Calidi Biotherapeutics, Inc. Enters into Lease Termination Agreement with 4475 Executive Drive LLC	CI
07-16	Calidi Biotherapeutics, Inc. Enters Into New Lease For Office And Laboratory Space In San Diego	CI
06-24	Calidi Biotherapeutics Presents New Data On CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 At The T-Cell Engager Therapeutic Summit	CI
06-23	Calidi Biotherapeutics, Inc. Announces Appointment of Corsee Sanders to Board of Directors and Member of the Audit Committee, Effective June 17, 2026	CI
06-16	Calidi Biotherapeutics, Inc. Receives Positive Pre-Ind Feedback From US FDA For CLD-401 And Advances Ind-Enabling Studies Towards First-In-Human Study	CI
06-16	Calidi Biotherapeutics Receives Positive Feedback From FDA for CLD-401 Pre-IND Application	MT
05-14	Calidi Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-29	Calidi Biotherapeutics announces strategic partnership with Transferai	RE
04-21	Calidi Biotherapeutics Presents New Data on Cld-401 At the Aacr Annual Meeting	CI
04-20	Certain Representative Warrants of Calidi Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-APR-2026.	CI
04-20	Certain Pre-Funded Warrants of Calidi Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-APR-2026.	CI

07-27	Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference	AQ
07-22	Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers	AQ
07-21	Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers	AQ
07-20	Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026	AQ
07-08	Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711	AQ

1 day	+9.86%
1 week	+2.50%
1 month	-39.71%
3 months	-56.75%
6 months	-89.95%
Current year	-91.24%

1 week	1.48	1.93
1 month	1.48	2.48
Current year	1.48	19.68
1 year	1.48	117.12
3 years	1.48	26,477.86
5 years	1.48	26,477.86
10 years	1.48	26,477.86

CALIDI B Stock

Stocks

CLDI

US3207034089

Biotechnology & Medical Research

Valuation: CALIDI B

Chart: CALIDI B

Latest news : CALIDI B

Analysts' recommendations: CALIDI B

Press Releases: CALIDI B

Quotes and Performance

Course Extremes

Managers and Directors: CALIDI B

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/12/25	Allan Camaisa	Sell	Director	850	0.0238%
9/3/25	Andrew Jackson	Free	Chief Financial Officer	30,000	0.5942%
9/3/25	Antonio Santidrian	Free	Chief Technology Officer	35,000	0.6932%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CALIDI B	+9.86%	+2.50%	-98.57%	-99.99%	1.99M
WUXI APPTEC CO., LTD.	+2.35%	+2.74%	+33.41%	+79.20%	56.54B
ARGENX SE	-0.21%	-7.38%	+25.34%	+63.02%	53.6B
BIONTECH SE	-2.44%	+1.40%	-15.74%	-16.80%	22.91B
INSMED INCORPORATED	-2.85%	-7.78%	-8.09%	+346.36%	21.37B
WUXI BIOLOGICS (CAYMAN) INC.	+2.49%	-0.92%	+20.31%	-12.15%	20.27B
GENMAB A/S	+0.79%	-1.06%	+29.29%	-33.32%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.58%	-5.88%	+16.30%	+540.37%	14.75B
EXELIXIS, INC.	-5.25%	-4.23%	+46.41%	+169.05%	13.33B
PHARMAESSENTIA CORPORATION	+3.41%	-6.61%	+163.08%	+280.43%	13.53B
Average	+0.87%	-3.16%	+21.17%	+131.62%	23.39B
Weighted average by Cap.	+0.23%	-2.96%	+28.67%	+119.98%

	2024	2025
Net sales	-	-
Net income	-22.14M -19.25M -17.92M -16.45M -31.06M -2.11B -31.54M -211M -82.89M -1.05B -83.16M -81.33M -3.53B	-19.91M -17.3M -16.11M -14.79M -27.93M -1.9B -28.36M -190M -74.51M -946M -74.76M -73.12M -3.17B
Net Debt	-2.56M -2.22M -2.07M -1.9M -3.58M -244M -3.64M -24.37M -9.56M -121M -9.6M -9.38M -407M	-3.04M -2.64M -2.46M -2.26M -4.26M -290M -4.33M -28.96M -11.36M -144M -11.4M -11.15M -484M